AbbVie Inc
NYSE:ABBV

109.14 USD +0.38 USD ( +0.35% )

AbbVie Inc (NYSE:ABBV)

Add ABBV to Watchlist

Summary

Business Profile
AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois. [ Read More ]

Country

United States of America

Industry

Drug Manufacturers-General

Market Cap

193B USD

Enterprise Value

270B USD

Dividend Yield

5%

Buyback Yield

1%

Intrinsic Valuation

ABBV Intrinsic Value
Intrinsic value based on company cash flows

The intrinsic value of one ABBV stock under the base scenario is 268.26 USD. Compared to the current market price of 109.14 USD, the company's shares are unvervalued by 146%.

Analyst Rating

Analyst Price Target
ABBV Price Target

12 month price targets for ABBV stock made by Wall Street analysts. The average price target is 129.55 USD with a high forecast of 151.2 USD and a low forecast of 106.05 USD.

Lowest
Forecast
106.05 USD
Downside 3%
Average
Forecast
129.55 USD
Upside 19%
Highest
Forecast
151.2 USD
Upside 39%

Competitors

Competitors Valuation Chart
AbbVie Inc Competitors

Competitors Valuation Table
AbbVie Inc Competitors

Shareholder Return

Stock Performance
ABBV Price Statistics

ABBV Market
1 Week +2% +1%
6 Months -2% +8%
1 Year +30% +33%
3 Years +53% +71%

Stock Price
ABBV Price Chart

1M
6M
1Y
3Y
5Y

Forecasted Financials

Revenue
Forecast of Future Revenue

-
-
-
-
-
-
-
-

Net Income
Forecast of Future Net Income

-
-
-
-
-
-
-
-

AbbVie Inc Revenue and Net Income forecasts made by Wall Street analysts.